Skip to content

LQDA

Liquidia Corporation

NASDAQ · USHealthcareBiotechnology
$77.08-3.58%

Price as of Jul 20, 2026

LQDA growth

Liquidia Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+1936.7%
EBITDA
+148.4%
EBIT
+135.6%
EPS
+115.2%
Free cash flow
+138.3%
Operating cash flow
+148.4%

Forward estimates

Revenue
+10.8%
EBITDA
EPS
+656.4%

Three-year CAGR

Revenue
+115.0%
EBITDA
+62.6%
EBIT
+57.6%
Net income
+47.1%
EPS
+51.8%
Free cash flow
+59.3%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.